Aptus Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →See revenue, profit and what management said. You are viewing Q1 FY27.
AP

Aptus Pharma Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Aptus Pharma Q1 FY27: Revenue ₹32.20 Cr, PAT ₹2.87 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Based on Aptus Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹347
Market cap₹606 Cr
P/E131.2

The short version

Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore

From Aptus Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23)
  • Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23)
  • Revenue for FY26: ₹46.57 crore, up 89.7% YoY from ₹24.56 crore in FY25 (Page 26)
  • Outlook: Strategic growth roadmap targets Pan-India presence by March 2029 and global expansion by March 2028 across Asia, Africa, and Latin America (Page 28)

2 more points from Aptus Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).
  • The company has formal loan and licence agreements with two manufacturing units in Gujarat (Page 14).
  • Strategic Growth Roadmap aims for own manufacturing to constitute 20% by March 2028, strengthening quality control and supply-chain (Page 28).

2 more points from Aptus Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Aptus Pharma Ltd said on order book & pipeline — free account, 30 seconds.

What Aptus Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aptus Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aptus Pharma Ltd Q1 FY27 results?

Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore

What is Aptus Pharma Ltd share price analysis?

Aptus Pharma Ltd currently shows a neutral. The stock trades at a P/E of 131.2 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aptus Pharma Ltd planning capital expenditure?

Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).

Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.